Neumora Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a)
See Note 15 – Subsequent Event to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form
10-Q for information regarding the amendment to the loan and security agreement with K2 HealthVentures LLC.
(c)
Trading Arrangements
The following table describes, for the three months ended September 30, 2025, each trading arrangement for the purchase or sale of Company securities adopted, modified or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name(Title) · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Sold · Expiration Date | |||||
| Daljit (Bill) Singh Aurora(Chief Operating and Development Officer) | Amend(1) | August 7, 2025 | X | 114,703 | December 31, 2026 |
*Intended to satisfy the affirmative defense of Rule 10b5-1(c)
**Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
(1) Changed the timing and price limits of sales under the trading arrangement originally adopted on April 22, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.